Participants 112 158 7
patients with untreated acute myeloid leukemia
Participants 414 555 3
In 1996, survival data were updated from three prospective, randomized comparisons of idarubicin and daunorubicin that began in 1984 and 1985
Participants 582 637 5
Memorial Sloan-Kettering Cancer Center (MSKCC), the U.S
Participants 672 708 5
Southeastern Cancer Study Group (SEG
